Goldman Sachs Issues Buy Rating for Hologic, Noting Contributions from Gen-Probe Purchase | GenomeWeb

NEW YORK (GenomeWeb News) – Goldman Sachs has placed a Buy rating on Hologic with a six-month price target on its stock of $24, as the Gen-Probe acquisition, completed a week ago, is expected to accelerate top line growth.

Analyst Isaac Ro removed his previous Not Rated designation on the Bedford, Mass.-based company and increased revenue estimates for fiscal-year 2012 to $2.00 billion from an earlier estimate of $1.91 billion, but he lowered the EPS estimate to $1.36 from $1.38.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.